Posted On: 05/06/2014 4:23:00 PM
Post# of 273371
Galapagos Genomics N (GLPGF) 21.3500 $GLPGF
Charles River Laboratories acquires CRO services division of Galapagos for EUR129m cash
M2 - Thu Mar 13, 7:07AM CDT
Drug development company Charles River Laboratories International Inc (NYSE:CRL) announced today that it has entered into a definitive agreement to acquire the CRO (contract research organisation) services division of Galapagos NV (FRA: GXE.F) (OTC: GLPGF), which includes both Argenta and BioFocus.
AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease
PR Newswire - Fri May 17, 12:15AM CDT
Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. Upon successful completion of the study, expected in Q2 2015, AbbVie will pay Galapagos $50 million. The terms of the collaboration extension are in addition to previously agreed upon financial terms. AbbVie will be responsible for funding and performing clinical development beyond Phase 2, and completing regulatory and commercialization activities.
Galapagos announces receipt of EUR2.7m IWT grant for antibacterial research
M2 - Thu Jan 10, 5:22AM CST
Galapagos NV (Euronext:GLPG)(OTC:GLPGF), a mid-size clinical stage biotechnology company, announced today the award of a EUR2.7m grant from the Flemish agency for Innovation by Science and Technology (IWT) to discover new antibiotic treatments.
Charles River Laboratories acquires CRO services division of Galapagos for EUR129m cash
M2 - Thu Mar 13, 7:07AM CDT
Drug development company Charles River Laboratories International Inc (NYSE:CRL) announced today that it has entered into a definitive agreement to acquire the CRO (contract research organisation) services division of Galapagos NV (FRA: GXE.F) (OTC: GLPGF), which includes both Argenta and BioFocus.
AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease
PR Newswire - Fri May 17, 12:15AM CDT
Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. Upon successful completion of the study, expected in Q2 2015, AbbVie will pay Galapagos $50 million. The terms of the collaboration extension are in addition to previously agreed upon financial terms. AbbVie will be responsible for funding and performing clinical development beyond Phase 2, and completing regulatory and commercialization activities.
Galapagos announces receipt of EUR2.7m IWT grant for antibacterial research
M2 - Thu Jan 10, 5:22AM CST
Galapagos NV (Euronext:GLPG)(OTC:GLPGF), a mid-size clinical stage biotechnology company, announced today the award of a EUR2.7m grant from the Flemish agency for Innovation by Science and Technology (IWT) to discover new antibiotic treatments.
(0)
(0)
